TNF inhibitors for inflammatory arthritis in New Zealand

New Zealand Medical Journal

Volumn 118, Issue 1224, 2005, Pages

  Grainger, Rebecca ^a   Harrison, Andrew ^b  

^a HUTT HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEMYELINATING DISEASE; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REGIMEN; FEVER; HUMAN; INFECTION COMPLICATION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; KINESIOTHERAPY; MYCOBACTERIOSIS; NAUSEA; NEW ZEALAND; PAIN ASSESSMENT; PANCYTOPENIA; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; RASH; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG SCREENING; ECONOMICS; METHODOLOGY; PUBLIC HEALTH; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG APPROVAL; DRUG EVALUATION; HUMANS; IMMUNOGLOBULIN G; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744447970     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Access Economics Pty Limited. The economic cost of arthritis in New Zealand. Arthritis New Zealand; June 2005.
2. Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983;309:1023-8.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16.
4. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
5. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187-93.
6. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005;64:229-34.
7. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93.
8. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999: 130:478-86.
9. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56.
10. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90.
11. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
12. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004;30:237-55, v.
13. Colombel JF, Loftus EV, Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
14. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013-22.
15. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.[see comment]. N Engl J Med. 2001;345:1098-104.
16. Grocott R. Final hospital pharmaceutical assessment summary-discussion document no. 12. Wellington: PHARMAC: February 2005.